Commitments and Contingencies

Operating Leases

The Company leases 38,613 square feet of office and laboratory space in San Diego, California, under a lease that terminates on April 30, 2032. As of December 31, 2025, the right-of-use asset balance associated with this lease was $3,322,249.

The Company currently also leases office space in Cambridge, Massachusetts and New York, New York, pursuant to short-term arrangements. In September 2025, the Company executed a one year lease for its existing office space in Cambridge with a term that commenced on December 1, 2025 and ends on November 30, 2026. The New York lease was most recently renewed on October 1, 2025 to extend the lease term through September 30, 2026. These lease agreements include or included payments for lease and non-lease components. The Company has elected to not separate such components and these payments were recognized as rent expense.

As of December 31, 2025, total future minimum lease payments for its short-term leases in Cambridge, Massachusetts and New York, New York were $140,136 due in 2026.

Future minimum lease payments for operating leases with initial or remaining terms in excess of one year at December 31, 2025 were as follows:


	Amount
2026	$	761,877
2027	784,737
2028	808,278
2029	832,527
2030	857,496
Thereafter	1,184,208
Total future lease payments	5,229,123
Less: Imputed interest	(1,404,698)
Total lease liabilities	$	3,824,425
Current portion lease liabilities	397,104
Lease liabilities, noncurrent	3,427,321
Total lease liabilities	$	3,824,425

Quantitative information regarding the Company’s leases for the year ended December 31, 2025 and 2024 is as follows:


	December 31, 2025			December 31, 2024
Lease costs:
Operating lease cost	$	746,360		$	760,822
Short-term lease cost	146,422			145,070
Sublease income	—			(19,200)
Total lease costs	$	892,782		$	886,692
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	739,689		$	732,546
Operating cash flows from short-term leases	146,422			145,070
	$	886,111		$	877,616
Weighted-average remaining lease term - operating leases	6.33 years			7.33 years
Weighted-average discount rate - operating leases	10.0		%	10.0		%

As the Company’s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

Litigation

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities and may be exposed to litigation in connection with its product candidates and operations. The Company’s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. When it is probable that future expenditures will be made and can be reasonably estimated, the Company will accrue a liability for such matters. Significant judgment is required to determine both probability and estimated amount. The Company is not aware of any material legal matters.

Clinical Research Contracts

The Company may enter into contracts in the normal course of business with contract research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies, supplies and other services for the Company's operating purposes. These contracts generally provide for termination with a 30-day notice.

Historical Timeline

Fiscal Year	Filed
2025	Mar 6, 2026	Showing above
2024	Mar 20, 2025

2023	Mar 1, 2024

2022	Mar 6, 2023

2021	Mar 10, 2022

About Commitments Disclosures

Commitments and contingencies disclosures catalog a company's off-balance-sheet obligations and legal exposures — purchase commitments, guarantee arrangements, pending litigation, and regulatory proceedings. These items represent potential future cash outflows that may not appear as liabilities on the balance sheet until they become probable and estimable.

Key signals: litigation reserves and disclosed loss ranges quantify management's estimate of legal exposure, but unquantified "reasonably possible" losses often represent the larger risk. Watch for changes in language around pending cases — shifts from "remote" to "reasonably possible" or increases in estimated loss ranges signal deteriorating outcomes. Unconditional purchase obligations and take-or-pay contracts create fixed cost structures that reduce operational flexibility. Guarantee arrangements for subsidiaries or joint ventures can create cascading obligations. Compare the total commitment schedule against projected free cash flow to assess whether the company can meet its obligations without additional financing.

Immuneering Corp Commitments Disclosure

Historical Timeline

About Commitments Disclosures

Other Available Disclosures